JPMorgan lowered the firm’s price target on Pfizer to $41 from $45 and keeps a Neutral rating on the shares ahead of the Q2 report. The analyst is modestly below consensus on COVID franchise sales.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Arcturus Therapeutics price target raised to $45 from $35 at Wells Fargo
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Seagen, Pfizer receive Second Request from FTC regarding merger
- Cantor says Arcturus’ detailed booster data validate STARR/LUNAR platforms
- Arcturus to receive booster approval in Japan this year, says H.C. Wainwright